189 related articles for article (PubMed ID: 22929916)
1. Bone metastasis in breast cancer: the story of RANK-ligand.
Azim HA; Kamal NS; Azim HA
J Egypt Natl Canc Inst; 2012 Sep; 24(3):107-14. PubMed ID: 22929916
[TBL] [Abstract][Full Text] [Related]
2. RANK ligand is a prerequisite for cancer-associated osteolytic lesions.
Kitazawa S; Kitazawa R
J Pathol; 2002 Oct; 198(2):228-36. PubMed ID: 12237883
[TBL] [Abstract][Full Text] [Related]
3. RANKL inhibition combined with tamoxifen treatment increases anti-tumor efficacy and prevents tumor-induced bone destruction in an estrogen receptor-positive breast cancer bone metastasis model.
Canon J; Bryant R; Roudier M; Branstetter DG; Dougall WC
Breast Cancer Res Treat; 2012 Oct; 135(3):771-80. PubMed ID: 22926264
[TBL] [Abstract][Full Text] [Related]
4. Betulinic acid, a bioactive pentacyclic triterpenoid, inhibits skeletal-related events induced by breast cancer bone metastases and treatment.
Park SY; Kim HJ; Kim KR; Lee SK; Lee CK; Park KK; Chung WY
Toxicol Appl Pharmacol; 2014 Mar; 275(2):152-62. PubMed ID: 24463094
[TBL] [Abstract][Full Text] [Related]
5. Denosumab: benefits of RANK ligand inhibition in cancer patients.
Lipton A; Jacobs I
Curr Opin Support Palliat Care; 2011 Sep; 5(3):258-64. PubMed ID: 21826000
[TBL] [Abstract][Full Text] [Related]
6. 15-deoxy-δ12,14-prostaglandin j2 inhibits osteolytic breast cancer bone metastasis and estrogen deficiency-induced bone loss.
Kim KR; Kim HJ; Lee SK; Ma GT; Park KK; Chung WY
PLoS One; 2015; 10(4):e0122764. PubMed ID: 25859665
[TBL] [Abstract][Full Text] [Related]
7. Molecular mechanisms of breast cancer metastases to bone.
Guise TA; Kozlow WM; Heras-Herzig A; Padalecki SS; Yin JJ; Chirgwin JM
Clin Breast Cancer; 2005 Feb; 5 Suppl(2):S46-53. PubMed ID: 15807924
[TBL] [Abstract][Full Text] [Related]
8. [Molecular mechanism and potential targets for bone metastasis].
Iguchi H
Gan To Kagaku Ryoho; 2007 Jan; 34(1):1-10. PubMed ID: 17220661
[TBL] [Abstract][Full Text] [Related]
9. Role of the RANK/RANKL pathway in breast cancer.
Kiesel L; Kohl A
Maturitas; 2016 Apr; 86():10-6. PubMed ID: 26921922
[TBL] [Abstract][Full Text] [Related]
10. Updates on the role of receptor activator of nuclear factor κB/receptor activator of nuclear factor κB ligand/osteoprotegerin pathway in breast cancer risk and treatment.
Bayer CM; Beckmann MW; Fasching PA
Curr Opin Obstet Gynecol; 2017 Feb; 29(1):4-11. PubMed ID: 28002265
[TBL] [Abstract][Full Text] [Related]
11. Expression profile of receptor activator of nuclear-κB (RANK), RANK ligand (RANKL) and osteoprotegerin (OPG) in breast cancer.
Owen S; Ye L; Sanders AJ; Mason MD; Jiang WG
Anticancer Res; 2013 Jan; 33(1):199-206. PubMed ID: 23267146
[TBL] [Abstract][Full Text] [Related]
12. Receptor activator of NF-kappaB ligand enhances breast cancer-induced osteolytic lesions through upregulation of extracellular matrix metalloproteinase inducer/CD147.
Rucci N; Millimaggi D; Mari M; Del Fattore A; Bologna M; Teti A; Angelucci A; Dolo V
Cancer Res; 2010 Aug; 70(15):6150-60. PubMed ID: 20631064
[TBL] [Abstract][Full Text] [Related]
13. Molecular mechanisms of osteolytic bone metastases.
Guise TA
Cancer; 2000 Jun; 88(12 Suppl):2892-8. PubMed ID: 10898330
[TBL] [Abstract][Full Text] [Related]
14. Involvement of cell-cell and cell-matrix interactions in bone destruction induced by metastatic MDA-MB-231 human breast cancer cells in nude mice.
Nakamura H; Hiraga T; Ninomiya T; Hosoya A; Fujisaki N; Yoneda T; Ozawa H
J Bone Miner Metab; 2008; 26(6):642-7. PubMed ID: 18979165
[TBL] [Abstract][Full Text] [Related]
15. Bisphosphonates as treatment of bone metastases.
Holen I; Coleman RE
Curr Pharm Des; 2010; 16(11):1262-71. PubMed ID: 20166976
[TBL] [Abstract][Full Text] [Related]
16. RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes.
Armstrong AP; Miller RE; Jones JC; Zhang J; Keller ET; Dougall WC
Prostate; 2008 Jan; 68(1):92-104. PubMed ID: 18008334
[TBL] [Abstract][Full Text] [Related]
17. Breast cancer metastasis to bone: it is not all about PTHrP.
Bendre M; Gaddy D; Nicholas RW; Suva LJ
Clin Orthop Relat Res; 2003 Oct; (415 Suppl):S39-45. PubMed ID: 14600591
[TBL] [Abstract][Full Text] [Related]
18. Molecular mechanisms of tumor-bone interactions in osteolytic metastases.
Chirgwin JM; Guise TA
Crit Rev Eukaryot Gene Expr; 2000; 10(2):159-78. PubMed ID: 11186331
[TBL] [Abstract][Full Text] [Related]
19. The RANK/RANKL/OPG triad in cancer-induced bone diseases.
Dougall WC; Chaisson M
Cancer Metastasis Rev; 2006 Dec; 25(4):541-9. PubMed ID: 17180711
[TBL] [Abstract][Full Text] [Related]
20. Targeting the receptor activator of nuclear factor-kappaB (RANK) ligand in prostate cancer bone metastases.
Saad F; Markus R; Goessl C
BJU Int; 2008 May; 101(9):1071-5. PubMed ID: 18070191
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
